These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33305703)

  • 1. Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders.
    Muheem A; Jahangir MA; Jaiswal CP; Jafar M; Ahmad MZ; Ahmad J; Warsi MH
    Curr Drug Metab; 2021; 22(4):263-279. PubMed ID: 33305703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders.
    Sharma A; Manchanda R; Pottoo FH; Ashraf GM
    Curr Drug Metab; 2021; 22(4):251-262. PubMed ID: 33234099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine based nanoparticles for neurological disorders.
    Sriramoju B; Kanwar RK; Kanwar JR
    Curr Med Chem; 2014; 21(36):4154-68. PubMed ID: 25039778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Rationalized Brain Targeted Nanoparticles in Neurological Disorders (Part-III).
    Javed MN; Ashraf GM; Barreto GE; Naim MJ
    Curr Drug Metab; 2021; 22(4):250. PubMed ID: 34170805
    [No Abstract]   [Full Text] [Related]  

  • 6. Nanotheranostics, a future remedy of neurological disorders.
    Sharma M; Dube T; Chibh S; Kour A; Mishra J; Panda JJ
    Expert Opin Drug Deliv; 2019 Feb; 16(2):113-128. PubMed ID: 30572726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS.
    Nabi B; Rehman S; Pottoo FH; Baboota S; Ali J
    Curr Drug Metab; 2021; 22(4):280-286. PubMed ID: 32964821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Analysis of Peptide-Modified Nanoparticles with Engineered Physicochemical Properties in a Mouse Model of Traumatic Brain Injury.
    Waggoner LE; Madias MI; Hurtado AA; Kwon EJ
    AAPS J; 2021 Aug; 23(5):100. PubMed ID: 34401968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for drug delivery to the central nervous system by systemic route.
    Kasinathan N; Jagani HV; Alex AT; Volety SM; Rao JV
    Drug Deliv; 2015 May; 22(3):243-57. PubMed ID: 24471801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
    Hassanzadeh P; Atyabi F; Dinarvand R
    Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Nanoparticle-based Drug Delivery Systems for Precision Medicine.
    Yang J; Jia C; Yang J
    Int J Med Sci; 2021; 18(13):2943-2949. PubMed ID: 34220321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders.
    Kumar S; Singh P; Sharma S; Pottoo FH; Ali J; Baboota S
    Comb Chem High Throughput Screen; 2021; 24(10):1544-1556. PubMed ID: 33334281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing nano-sized chemotherapy.
    Gewin V
    Nature; 2021 May; 593(7859):470. PubMed ID: 34002085
    [No Abstract]   [Full Text] [Related]  

  • 14. Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.
    Ghalamfarsa G; Hojjat-Farsangi M; Mohammadnia-Afrouzi M; Anvari E; Farhadi S; Yousefi M; Jadidi-Niaragh F
    J Immunotoxicol; 2016 Sep; 13(5):603-19. PubMed ID: 27416019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal.
    Kanwar JR; Sun X; Punj V; Sriramoju B; Mohan RR; Zhou SF; Chauhan A; Kanwar RK
    Nanomedicine; 2012 May; 8(4):399-414. PubMed ID: 21889479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain safety concerns of nanomedicines: The need for a specific regulatory framework.
    Szabat-Iriaka B; Le Borgne M
    Drug Discov Today; 2021 Nov; 26(11):2502-2507. PubMed ID: 34224902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: A review.
    Ashrafizadeh M; Mohammadinejad R; Kailasa SK; Ahmadi Z; Afshar EG; Pardakhty A
    Adv Colloid Interface Sci; 2020 Apr; 278():102123. PubMed ID: 32087367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Nanodrug Delivery Systems Production, Efficacy, Safety, and Toxicity.
    Lopalco A; Iacobazzi RM; Lopedota AA; Denora N
    Methods Mol Biol; 2025; 2834():303-332. PubMed ID: 39312172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patents on brain permeable nanoparticles.
    Gulati M; Chopra DS; Singh SK; Saluja V; Pathak P; Bansal P
    Recent Pat CNS Drug Discov; 2013 Dec; 8(3):220-34. PubMed ID: 24286450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global research on artemisinin and its derivatives: Perspectives from patents.
    Liu K; Zuo H; Li G; Yu H; Hu Y
    Pharmacol Res; 2020 Sep; 159():105048. PubMed ID: 32590098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.